BJ Bioscience Inc. announced that the first patient was successfully dosed on December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001 program at NEXT ONCOLOGY in San Antonio, Texas.
CMAB Biopharma (Suzhou) Inc. ("CMAB"), a pure-play biologics CDMO and BJ Bioscience Inc. ("BJ Bioscience"), an innovative biopharmaceutical enterprise ...